Skip to content

The Market Herald – Proteomics (ASX:PIQ) validates prognostic diabetes kidney test

“Proteomics International Laboratories (PIQ) reports its PromarkerD predictive test for diabetic kidney disease has been validated in a major clinical study. The successful trial is another positive step towards Food and Drug Administration (FDA) approval in the U.S.“

Article: Proteomics (ASX:PIQ) validates prognostic diabetes kidney test